Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ACER | Acer Therapeutics Inc.

Index- P/E- EPS (ttm)-1.95 Insider Own19.50% Shs Outstand24.46M Perf Week-1.15%
Market Cap19.70M Forward P/E6.92 EPS next Y0.12 Insider Trans0.00% Shs Float21.11M Perf Month25.78%
Income-38.80M PEG- EPS next Q-0.12 Inst Own26.10% Short Float / Ratio3.40% / 0.31 Perf Quarter-8.74%
Sales- P/S- EPS this Y-54.40% Inst Trans0.70% Short Interest0.72M Perf Half Y10.71%
Book/sh-1.36 P/B- EPS next Y116.70% ROA-270.70% Target Price1.50 Perf Year-38.50%
Cash/sh0.07 P/C12.31 EPS next 5Y- ROE175.50% 52W Range0.55 - 4.56 Perf YTD-66.92%
Dividend- P/FCF- EPS past 5Y2.50% ROI- 52W High-81.79% Beta0.50
Dividend %- Quick Ratio0.00 Sales past 5Y- Gross Margin- 52W Low50.55% ATR0.11
Employees33 Current Ratio0.20 Sales Q/Q- Oper. Margin- RSI (14)49.71 Volatility4.59% 14.62%
OptionableYes Debt/Eq- EPS Q/Q-89.40% Profit Margin- Rel Volume0.06 Prev Close0.83
ShortableYes LT Debt/Eq- EarningsAug 14 AMC Payout- Avg Volume2.34M Price0.83
Recom2.50 SMA200.30% SMA502.17% SMA200-40.18% Volume132,299 Change-0.25%
Date Action Analyst Rating Change Price Target Change
Jun-26-19Reiterated H.C. Wainwright Buy $55 → $10
Jun-25-19Downgrade William Blair Outperform → Mkt Perform
Jun-25-19Downgrade Raymond James Outperform → Mkt Perform
May-23-19Initiated Wedbush Outperform
Feb-15-19Resumed Raymond James Outperform $40
Dec-20-18Initiated Needham Buy $48
Feb-26-18Initiated ROTH Capital Buy
Dec-20-17Initiated H.C. Wainwright Buy $50
Aug-31-23 12:13PM
Aug-30-23 04:05PM
Aug-15-23 12:29PM
Aug-14-23 04:05PM
08:30AM Loading…
Jun-26-23 08:30AM
May-15-23 05:10PM
May-01-23 08:30AM
Apr-26-23 11:59AM
Mar-31-23 06:00PM
Mar-27-23 04:01PM
Mar-22-23 08:30AM
Mar-20-23 12:01PM
Mar-17-23 01:34PM
08:30AM Loading…
Mar-15-23 08:30AM
Mar-10-23 05:50PM
Feb-23-23 05:50PM
Feb-22-23 06:00PM
Feb-13-23 08:30AM
Feb-10-23 05:50PM
Feb-01-23 05:50PM
Jan-31-23 08:00AM
Jan-27-23 07:05AM
Jan-25-23 06:00PM
Jan-19-23 06:00PM
Jan-18-23 08:49AM
09:40AM Loading…
Jan-16-23 09:40AM
Jan-10-23 06:00PM
Jan-09-23 08:30AM
Jan-05-23 08:30AM
Dec-29-22 09:40AM
Dec-28-22 12:00PM
Dec-27-22 08:30AM
Dec-23-22 02:47PM
Dec-13-22 09:40AM
Dec-08-22 09:35PM
Dec-04-22 07:17AM
Nov-30-22 08:30AM
Nov-17-22 05:37AM
Nov-14-22 05:08PM
Oct-26-22 08:30AM
Oct-18-22 04:05PM
Oct-06-22 08:30AM
Oct-05-22 01:44PM
Oct-03-22 08:30AM
Sep-30-22 11:47AM
Sep-29-22 11:42AM
Sep-15-22 01:28PM
Sep-13-22 11:58AM
Aug-23-22 08:30AM
Aug-15-22 04:00PM
Aug-12-22 08:30AM
Jul-28-22 08:33AM
Jul-18-22 08:30AM
Jul-15-22 06:15AM
Jul-08-22 08:30AM
Jun-28-22 06:16AM
Jun-27-22 08:30AM
Jun-23-22 08:14AM
Jun-22-22 09:43AM
Jun-21-22 01:12PM
Jun-15-22 08:49AM
Jun-09-22 05:18AM
Jun-07-22 08:30AM
Jun-06-22 06:05AM
May-16-22 06:55PM
May-12-22 08:15AM
May-09-22 08:30AM
May-06-22 08:30AM
May-05-22 08:30AM
Apr-12-22 08:30AM
Apr-11-22 03:48PM
Apr-04-22 08:30AM
Mar-31-22 08:30AM
Mar-30-22 08:30AM
Mar-28-22 07:00AM
Mar-07-22 06:15AM
Mar-02-22 05:18PM
Feb-22-22 08:30AM
Feb-08-22 02:44PM
Feb-01-22 08:30AM
Jan-27-22 08:30AM
Jan-13-22 09:40AM
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schelling ChrisPresident & CEONov 29Buy1.22819,6721,000,0002,712,529Dec 01 04:02 PM
ASELAGE STEVEDirectorNov 29Buy1.22409,836500,000483,741Dec 01 04:01 PM